Catálogo de publicaciones - revistas

<jats:p>This study investigates the pharmacokinetics of eslicarbazepine acetate (ESL), a new voltage‐gated sodium channel blocker, in epileptic children aged 2 to 7 years (n = 11) and 7 to 11 years (n = 8) and adolescents aged 12 to 17 years (n = 10). The study explores ESL efficacy and tolerability. Patients were treated with ESL once‐daily doses of 5 mg/kg/day on weeks 1 to 4, 15 mg/kg/day on weeks 5 to 8, and 30 mg/kg/day (or 1800 mg/day, whichever was less) on weeks 9 to 12. At the end of each 4‐week period, a 24‐hour pharmacokinetic profiling was performed. Similar to adults, ESL was rapidly metabolized to eslicarbazepine. In all age groups, eslicarbazepine peak concentrations were reached 0.5 hour to 3 hours after ESL dosing, and C<jats:sub>max</jats:sub> and AUC<jats:sub>0–24</jats:sub> were dose proportional. Eslicarbazepine C<jats:sub>max</jats:sub> was similar between age groups following administration of identical ESL dose/kg, but AUC<jats:sub>0–24</jats:sub> depended on age due to a faster plasma clearance of eslicarbazepine in younger children compared with adolescents. R‐licarbazepine and oxcarbazepine were minor metabolites. A dose‐dependent decrease in seizure frequency was observed in children aged 2 to 7 years and adolescents aged 12 to 17 years but not in children aged 7 to 11 years. One patient in each group became seizure free. ESL was generally well tolerated.</jats:p>